In a female patient with myocardial infarction with nonobstructive coronary arteries (MINOCA), hypertension, coronary microvascular dysfunction, and preserved ejection fraction, should I use nebivolol or bisoprolol?

Beta-Blocker Selection in MINOCA with Coronary Microvascular Dysfunction

Either bisoprolol or nebivolol is appropriate for this patient, as both are recommended beta-blockers for MINOCA with coronary microvascular dysfunction (CMD), and there is no evidence demonstrating superiority of one over the other for mortality or morbidity outcomes in this specific population.

Guideline-Based Recommendation

The 2024 Canadian Cardiovascular Society/Canadian Women's Heart Health Alliance MINOCA guidelines explicitly recommend beta-blockers as first-line therapy for CMD 1. The guidelines state that "improvement in chest pain has been reported with first line antianginals such as β-blockers" and list beta-blockers among agents that "may be considered" for angina control and quality of life in MINOCA secondary to CMD 1.

Key Points from Guidelines:

• For CMD specifically: Beta-blockers are recommended alongside calcium channel blockers, nitrates, and ranolazine for symptom control 1
• For hypertension management: Beta-blockers are appropriate, particularly given this patient's post-MI status 1
• No specific beta-blocker preference: The guidelines do not distinguish between bisoprolol and nebivolol for MINOCA or CMD 1

Evidence Analysis

Lack of Head-to-Head Comparison

A 2022 systematic review found that "head-to-head trials are largely lacking" between bisoprolol and nebivolol, with "no clear indication from published studies of an additional effect of nebivolol on clinical outcomes" 2. This applies to heart failure, hypertension, and ischemic heart disease—none of which showed meaningful clinical outcome differences.

Recent Post-MI Data with Preserved EF

Three major 2024-2025 trials (REDUCE-AMI, BETAMI, and their meta-analysis) evaluated beta-blockers after MI with preserved ejection fraction (≥50%), using bisoprolol or metoprolol 3, 4, 5. These trials showed:

• No mortality benefit (HR 1.04-1.06)
• No reduction in reinfarction (HR 0.89-1.01)
• No reduction in heart failure hospitalization (HR 0.87-0.89)

Importantly, nebivolol was not studied in these landmark trials, meaning we lack contemporary evidence for nebivolol specifically in post-MI patients with preserved EF.

Nebivolol's Theoretical Advantages

Nebivolol has vasodilatory properties through nitric oxide release 2, 6, which theoretically could benefit CMD (characterized by endothelial dysfunction). However, this has not translated into superior clinical outcomes in comparative studies 2.

Practical Decision-Making Algorithm

Choose bisoprolol if:

• You want the beta-blocker with the most robust post-MI evidence in contemporary trials 3, 4, 5
• Cost is a consideration (bisoprolol is typically less expensive)
• The patient has no specific contraindications

Choose nebivolol if:

• The patient has significant peripheral vascular disease (nebivolol's vasodilatory properties may theoretically be advantageous, though not proven) 2
• The patient has metabolic concerns (nebivolol has neutral metabolic effects) 6
• Previous intolerance to bisoprolol

Dosing considerations:

• Bisoprolol: Start 2.5-5 mg daily, titrate to target 10 mg daily for hypertension
• Nebivolol: Start 5 mg daily, titrate to 10-40 mg daily as tolerated

Important Caveats

Preserved EF Context

Your patient has preserved ejection fraction, and recent evidence suggests beta-blockers may provide less benefit than historically assumed in this population 3, 4, 5. However, the guidelines still recommend them for:

1. Symptom control in CMD (angina management) 1
2. Hypertension management 1
3. Post-MI secondary prevention (though benefit is less certain with preserved EF) 1

Women-Specific Considerations

MINOCA occurs predominantly in women (>90% in some SCAD cases) 1, and women experience more coronary microvascular dysfunction 7. The guidelines emphasize that beta-blockers remain appropriate therapy regardless of sex 1.

Monitoring Requirements

Both agents require monitoring for:

• Bradycardia (both are contraindicated in severe bradycardia) 8, 9
• Heart block (contraindicated if >first degree) 8, 9
• Hypotension (monitor blood pressure closely)
• Bronchospasm (use caution; both are beta-1 selective but not absolutely selective) 9

Drug Label Warnings

Bisoprolol specifically warns against abrupt cessation in coronary artery disease patients due to risk of angina exacerbation, MI, or arrhythmia 9. Taper over approximately one week if discontinuation is necessary 9.

Bottom Line

Select based on availability, cost, and patient-specific factors rather than expecting meaningful outcome differences. Both bisoprolol and nebivolol are guideline-recommended beta-blockers for your patient's presentation 1. The choice between them should be pragmatic rather than evidence-based, as no superiority data exists for MINOCA with CMD specifically 2.